Share on StockTwits

Smith & Nephew plc (ADR) (NYSE:SNN)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a research report issued on Monday. They currently have a $82.00 price target on the stock, up from their previous price target of $81.00. Canaccord Genuity’s target price points to a potential upside of 4.83% from the stock’s previous close.

SNN has been the subject of a number of other recent research reports. Analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc (ADR) in a research note on Tuesday, May 13th. Separately, analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc (ADR) in a research note on Thursday, May 1st. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc (ADR) in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $82.50.

Smith & Nephew plc (NYSE:SNN) traded down 1.10% on Monday, hitting $77.36. 24,316 shares of the company’s stock traded hands. Smith & Nephew plc has a one year low of $55.22 and a one year high of $80.42. The stock’s 50-day moving average is $76.2 and its 200-day moving average is $73.12. The company has a market cap of $13.816 billion and a P/E ratio of 25.07.

Smith & Nephew plc (ADR) (NYSE:SNN) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.89 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.93 by $0.04. Analysts expect that Smith & Nephew plc will post $4.12 EPS for the current fiscal year.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.